# ASCENT-03 (NCT05382299)

> Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05382299
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gilead Sciences
- Conditions: Triple Negative Breast Cancer; PD-L1 Negative
- Interventions: Sacituzumab Govitecan-hziy; Paclitaxel; nab-Paclitaxel; Gemcitabine; Carboplatin
- Enrollment: 623
- Primary outcome: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

## Commentary we found

- X threads: 126
- YouTube: 85
- Podcasts: 63
- X videos: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ascent-03-nct05382299

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05382299", "email": "<work email>"}; the inbox owner confirms by the emailed link.